Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy

NCT06846086 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-03-26

No results posted yet for this study

Summary

The aim of current study is to: Evaluate the cardioprotective effects of melatonin in patients with cardiomyopathy.

Conditions

  • Cardiomyopathies

Interventions

DRUG

Melatonin 10 MG

Melatonin

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2026-01-01
Completion
2026-02-01

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06846086 on ClinicalTrials.gov